OperaV1, PascalFrancis, Checkpoint, bibRecord, 000121

Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial

Identifieur interne : 000121 ( PascalFrancis/Checkpoint ); précédent : 000120; suivant : 000122

Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial

Auteurs : Michael Manns [Allemagne] ; Henk Reesink [Pays-Bas] ; Thomas Berg [Allemagne] ; Geoffrey Dusheiko [Royaume-Uni] ; Robert Flisiak [Pologne] ; Patrick Marcellin [France] ; Christophe Moreno [Belgique] ; Oliver Lenz [Belgique] ; Paul Meyvisch [Belgique] ; Monika Peeters [Belgique] ; Vanitha Sekar [États-Unis] ; Kenneth Simmen [Irlande (pays)] ; Rene Verloes [Belgique]

Source :

Antiviral therapy : (London) [ 1359-6535 ] ; 2011.

RBID : Pascal:11-0504707

Descripteurs français

Pascal (Inist)
- Dose journalière unique, Association médicamenteuse, Forme pégylée, Cytokine, Interféron, Ribavirine, Hépatite virale C, Génotype, Typage, Homme, Malade, Randomisation, Antiviral.
Wicri :
- topic : Homme.

English descriptors

KwdEn :
- Antiviral, Cytokine, Drug combination, Genotype, Human, Interferon, Patient, Pegylated form, Randomization, Ribavirin, Single daily dose, Typing, Viral hepatitis C.

Abstract

Background: Antiviral activity of TMC435, an oral, once-daily, HCV NS3/4A protease inhibitor, was evaluated with pegylated interferon-α2a/ribavirin (P/R) in HCV genotype-1 patients. Methods: Optimal Protease inhibitor Enhancement of Response to TherApy (OPERA-1; TMC435-C201; NCT00561353) is a Phase IIa, randomized, placebo-controlled study. Treatment-naive patients (n=7₄) received 25, 75 or 200 mg TMC435 once daily, or placebo for 7 days followed by 21 days of triple therapy with P/R, or triple therapy for 28 days. Treatment-experienced patients (n=3₇; 56.8% with cirrhosis) received 75, 150 or 200 mg TMC435 once daily, or placebo with P/R for 28 days. Patients continued P/R up to week 48. Results: Treatment-naive patients who received initial monotherapy had a rapid decline in HCV RNA by day 3. At day 7, HCV RNA reductions were greatest for the 75 and 200 mg doses (0.02, -2.63, -3.43 and -4.13 log₁₀ IU/ml for placebo, and TMC435 25, 75 and 200 mg, respectively). At day 28, all patients who received triple therapy with TMC435 75 or 200 mg had HCV RNA<25 IU/ml versus 4/9 for placebo. In total, 18/28 treatment-experienced patients (9/9 prior relapsers, 9/19 non-responders) who received TMC435 had HCV RNA<25 IU/ml at day 28 versus 0/9 for placebo; similar results were observed for the 150 and 200 mg doses. Most adverse events were grade 1/2. No relevant changes in laboratory parameters occurred, except mild and reversible bilirubin elevations, mostly at the 200 mg dose. Conclusions: Once-daily TMC435 with P/R showed potent, dose-dependent antiviral activity over 28 days, and had a favourable tolerability profile.

Affiliations:

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: 000145
to stream PascalFrancis, to step Curation: 000400

Links to Exploration step

Pascal:11-0504707

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial</title>
<author><name sortKey="Manns, Michael" sort="Manns, Michael" uniqKey="Manns M" first="Michael" last="Manns">Michael Manns</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="2">Basse-Saxe</region>
<settlement type="city">Hanovre</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Reesink, Henk" sort="Reesink, Henk" uniqKey="Reesink H" first="Henk" last="Reesink">Henk Reesink</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Academic Medical Center</s1>
<s2>Amsterdam</s2>
<s3>NLD</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Berg, Thomas" sort="Berg, Thomas" uniqKey="Berg T" first="Thomas" last="Berg">Thomas Berg</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Department of Hepatology, Clinic of Gastroenterology and Rheumatology, University Clinic Leipzig</s1>
<s2>Leipzig</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="1">Saxe (Land)</region>
<region type="district" nuts="2">District de Leipzig</region>
<settlement type="city">Leipzig</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dusheiko, Geoffrey" sort="Dusheiko, Geoffrey" uniqKey="Dusheiko G" first="Geoffrey" last="Dusheiko">Geoffrey Dusheiko</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Royal Free Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Flisiak, Robert" sort="Flisiak, Robert" uniqKey="Flisiak R" first="Robert" last="Flisiak">Robert Flisiak</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Medical University of Biatystok</s1>
<s2>Białystok</s2>
<s3>POL</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Pologne</country>
<wicri:noRegion>Medical University of Biatystok</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Marcellin, Patrick" sort="Marcellin, Patrick" uniqKey="Marcellin P" first="Patrick" last="Marcellin">Patrick Marcellin</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Hôpital Beaujon</s1>
<s2>Clichy</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Clichy</wicri:noRegion>
<wicri:noRegion>Hôpital Beaujon</wicri:noRegion>
<wicri:noRegion>Hôpital Beaujon</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Moreno, Christophe" sort="Moreno, Christophe" uniqKey="Moreno C" first="Christophe" last="Moreno">Christophe Moreno</name>
<affiliation wicri:level="4"><inist:fA14 i1="07"><s1>Erasme Hospital, Université Libre de Bruxelles</s1>
<s2>Brussels</s2>
<s3>BEL</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<placeName><settlement type="city">Bruxelles</settlement>
<region nuts="2">Région de Bruxelles-Capitale</region>
</placeName>
<orgName type="university">Université libre de Bruxelles</orgName>
</affiliation>
</author>
<author><name sortKey="Lenz, Oliver" sort="Lenz, Oliver" uniqKey="Lenz O" first="Oliver" last="Lenz">Oliver Lenz</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Tibotec</s1>
<s2>Beerse</s2>
<s3>BEL</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>Tibotec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Meyvisch, Paul" sort="Meyvisch, Paul" uniqKey="Meyvisch P" first="Paul" last="Meyvisch">Paul Meyvisch</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Tibotec</s1>
<s2>Beerse</s2>
<s3>BEL</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>Tibotec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Peeters, Monika" sort="Peeters, Monika" uniqKey="Peeters M" first="Monika" last="Peeters">Monika Peeters</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Tibotec</s1>
<s2>Beerse</s2>
<s3>BEL</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>Tibotec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sekar, Vanitha" sort="Sekar, Vanitha" uniqKey="Sekar V" first="Vanitha" last="Sekar">Vanitha Sekar</name>
<affiliation wicri:level="2"><inist:fA14 i1="09"><s1>Tibotec Inc.</s1>
<s2>Titusville, NJ</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Simmen, Kenneth" sort="Simmen, Kenneth" uniqKey="Simmen K" first="Kenneth" last="Simmen">Kenneth Simmen</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Tibotec Pharmaceuticals Ltd, Eastgate Village</s1>
<s2>Cork</s2>
<s3>IRL</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Irlande (pays)</country>
<wicri:noRegion>Cork</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Verloes, Rene" sort="Verloes, Rene" uniqKey="Verloes R" first="Rene" last="Verloes">Rene Verloes</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Tibotec</s1>
<s2>Beerse</s2>
<s3>BEL</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>Tibotec</wicri:noRegion>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">11-0504707</idno>
<date when="2011">2011</date>
<idno type="stanalyst">PASCAL 11-0504707 INIST</idno>
<idno type="RBID">Pascal:11-0504707</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000145</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000400</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000121</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial</title>
<author><name sortKey="Manns, Michael" sort="Manns, Michael" uniqKey="Manns M" first="Michael" last="Manns">Michael Manns</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="2">Basse-Saxe</region>
<settlement type="city">Hanovre</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Reesink, Henk" sort="Reesink, Henk" uniqKey="Reesink H" first="Henk" last="Reesink">Henk Reesink</name>
<affiliation wicri:level="3"><inist:fA14 i1="02"><s1>Academic Medical Center</s1>
<s2>Amsterdam</s2>
<s3>NLD</s3>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Pays-Bas</country>
<placeName><settlement type="city">Amsterdam</settlement>
<region nuts="2" type="province">Hollande-Septentrionale</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Berg, Thomas" sort="Berg, Thomas" uniqKey="Berg T" first="Thomas" last="Berg">Thomas Berg</name>
<affiliation wicri:level="3"><inist:fA14 i1="03"><s1>Department of Hepatology, Clinic of Gastroenterology and Rheumatology, University Clinic Leipzig</s1>
<s2>Leipzig</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Allemagne</country>
<placeName><region type="land" nuts="1">Saxe (Land)</region>
<region type="district" nuts="2">District de Leipzig</region>
<settlement type="city">Leipzig</settlement>
</placeName>
</affiliation>
</author>
<author><name sortKey="Dusheiko, Geoffrey" sort="Dusheiko, Geoffrey" uniqKey="Dusheiko G" first="Geoffrey" last="Dusheiko">Geoffrey Dusheiko</name>
<affiliation wicri:level="3"><inist:fA14 i1="04"><s1>Royal Free Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Royaume-Uni</country>
<placeName><settlement type="city">Londres</settlement>
<region type="country">Angleterre</region>
<region type="région" nuts="1">Grand Londres</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Flisiak, Robert" sort="Flisiak, Robert" uniqKey="Flisiak R" first="Robert" last="Flisiak">Robert Flisiak</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Medical University of Biatystok</s1>
<s2>Białystok</s2>
<s3>POL</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Pologne</country>
<wicri:noRegion>Medical University of Biatystok</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Marcellin, Patrick" sort="Marcellin, Patrick" uniqKey="Marcellin P" first="Patrick" last="Marcellin">Patrick Marcellin</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Hôpital Beaujon</s1>
<s2>Clichy</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</inist:fA14>
<country>France</country>
<wicri:noRegion>Clichy</wicri:noRegion>
<wicri:noRegion>Hôpital Beaujon</wicri:noRegion>
<wicri:noRegion>Hôpital Beaujon</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Moreno, Christophe" sort="Moreno, Christophe" uniqKey="Moreno C" first="Christophe" last="Moreno">Christophe Moreno</name>
<affiliation wicri:level="4"><inist:fA14 i1="07"><s1>Erasme Hospital, Université Libre de Bruxelles</s1>
<s2>Brussels</s2>
<s3>BEL</s3>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<placeName><settlement type="city">Bruxelles</settlement>
<region nuts="2">Région de Bruxelles-Capitale</region>
</placeName>
<orgName type="university">Université libre de Bruxelles</orgName>
</affiliation>
</author>
<author><name sortKey="Lenz, Oliver" sort="Lenz, Oliver" uniqKey="Lenz O" first="Oliver" last="Lenz">Oliver Lenz</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Tibotec</s1>
<s2>Beerse</s2>
<s3>BEL</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>Tibotec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Meyvisch, Paul" sort="Meyvisch, Paul" uniqKey="Meyvisch P" first="Paul" last="Meyvisch">Paul Meyvisch</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Tibotec</s1>
<s2>Beerse</s2>
<s3>BEL</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>Tibotec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Peeters, Monika" sort="Peeters, Monika" uniqKey="Peeters M" first="Monika" last="Peeters">Monika Peeters</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Tibotec</s1>
<s2>Beerse</s2>
<s3>BEL</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>Tibotec</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Sekar, Vanitha" sort="Sekar, Vanitha" uniqKey="Sekar V" first="Vanitha" last="Sekar">Vanitha Sekar</name>
<affiliation wicri:level="2"><inist:fA14 i1="09"><s1>Tibotec Inc.</s1>
<s2>Titusville, NJ</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">New Jersey</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Simmen, Kenneth" sort="Simmen, Kenneth" uniqKey="Simmen K" first="Kenneth" last="Simmen">Kenneth Simmen</name>
<affiliation wicri:level="1"><inist:fA14 i1="10"><s1>Tibotec Pharmaceuticals Ltd, Eastgate Village</s1>
<s2>Cork</s2>
<s3>IRL</s3>
<sZ>12 aut.</sZ>
</inist:fA14>
<country>Irlande (pays)</country>
<wicri:noRegion>Cork</wicri:noRegion>
</affiliation>
</author>
<author><name sortKey="Verloes, Rene" sort="Verloes, Rene" uniqKey="Verloes R" first="Rene" last="Verloes">Rene Verloes</name>
<affiliation wicri:level="1"><inist:fA14 i1="08"><s1>Tibotec</s1>
<s2>Beerse</s2>
<s3>BEL</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
</inist:fA14>
<country>Belgique</country>
<wicri:noRegion>Tibotec</wicri:noRegion>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Antiviral therapy : (London)</title>
<title level="j" type="abbreviated">Antivir. ther. : (Lond.)</title>
<idno type="ISSN">1359-6535</idno>
<imprint><date when="2011">2011</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Antiviral therapy : (London)</title>
<title level="j" type="abbreviated">Antivir. ther. : (Lond.)</title>
<idno type="ISSN">1359-6535</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiviral</term>
<term>Cytokine</term>
<term>Drug combination</term>
<term>Genotype</term>
<term>Human</term>
<term>Interferon</term>
<term>Patient</term>
<term>Pegylated form</term>
<term>Randomization</term>
<term>Ribavirin</term>
<term>Single daily dose</term>
<term>Typing</term>
<term>Viral hepatitis C</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Dose journalière unique</term>
<term>Association médicamenteuse</term>
<term>Forme pégylée</term>
<term>Cytokine</term>
<term>Interféron</term>
<term>Ribavirine</term>
<term>Hépatite virale C</term>
<term>Génotype</term>
<term>Typage</term>
<term>Homme</term>
<term>Malade</term>
<term>Randomisation</term>
<term>Antiviral</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Background: Antiviral activity of TMC435, an oral, once-daily, HCV NS3/4A protease inhibitor, was evaluated with pegylated interferon-α2a/ribavirin (P/R) in HCV genotype-1 patients. Methods: Optimal Protease inhibitor Enhancement of Response to TherApy (OPERA-1; TMC435-C201; NCT00561353) is a Phase IIa, randomized, placebo-controlled study. Treatment-naive patients (n=7<sub>4</sub>
) received 25, 75 or 200 mg TMC435 once daily, or placebo for 7 days followed by 21 days of triple therapy with P/R, or triple therapy for 28 days. Treatment-experienced patients (n=3<sub>7</sub>
; 56.8% with cirrhosis) received 75, 150 or 200 mg TMC435 once daily, or placebo with P/R for 28 days. Patients continued P/R up to week 48. Results: Treatment-naive patients who received initial monotherapy had a rapid decline in HCV RNA by day 3. At day 7, HCV RNA reductions were greatest for the 75 and 200 mg doses (0.02, -2.63, -3.43 and -4.13 log<sub>10</sub>
 IU/ml for placebo, and TMC435 25, 75 and 200 mg, respectively). At day 28, all patients who received triple therapy with TMC435 75 or 200 mg had HCV RNA<25 IU/ml versus 4/9 for placebo. In total, 18/28 treatment-experienced patients (9/9 prior relapsers, 9/19 non-responders) who received TMC435 had HCV RNA<25 IU/ml at day 28 versus 0/9 for placebo; similar results were observed for the 150 and 200 mg doses. Most adverse events were grade 1/2. No relevant changes in laboratory parameters occurred, except mild and reversible bilirubin elevations, mostly at the 200 mg dose. Conclusions: Once-daily TMC435 with P/R showed potent, dose-dependent antiviral activity over 28 days, and had a favourable tolerability profile.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>1359-6535</s0>
</fA01>
<fA03 i2="1"><s0>Antivir. ther. : (Lond.)</s0>
</fA03>
<fA05><s2>16</s2>
</fA05>
<fA06><s2>7</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>MANNS (Michael)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>REESINK (Henk)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>BERG (Thomas)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>DUSHEIKO (Geoffrey)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>FLISIAK (Robert)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>MARCELLIN (Patrick)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>MORENO (Christophe)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>LENZ (Oliver)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>MEYVISCH (Paul)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>PEETERS (Monika)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>SEKAR (Vanitha)</s1>
</fA11>
<fA11 i1="12" i2="1"><s1>SIMMEN (Kenneth)</s1>
</fA11>
<fA11 i1="13" i2="1"><s1>VERLOES (Rene)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School</s1>
<s2>Hannover</s2>
<s3>DEU</s3>
<sZ>1 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Academic Medical Center</s1>
<s2>Amsterdam</s2>
<s3>NLD</s3>
<sZ>2 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Hepatology, Clinic of Gastroenterology and Rheumatology, University Clinic Leipzig</s1>
<s2>Leipzig</s2>
<s3>DEU</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Royal Free Hospital</s1>
<s2>London</s2>
<s3>GBR</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Medical University of Biatystok</s1>
<s2>Białystok</s2>
<s3>POL</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Hôpital Beaujon</s1>
<s2>Clichy</s2>
<s3>FRA</s3>
<sZ>6 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Erasme Hospital, Université Libre de Bruxelles</s1>
<s2>Brussels</s2>
<s3>BEL</s3>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="08"><s1>Tibotec</s1>
<s2>Beerse</s2>
<s3>BEL</s3>
<sZ>8 aut.</sZ>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
<sZ>13 aut.</sZ>
</fA14>
<fA14 i1="09"><s1>Tibotec Inc.</s1>
<s2>Titusville, NJ</s2>
<s3>USA</s3>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="10"><s1>Tibotec Pharmaceuticals Ltd, Eastgate Village</s1>
<s2>Cork</s2>
<s3>IRL</s3>
<sZ>12 aut.</sZ>
</fA14>
<fA20><s1>1021-1033</s1>
</fA20>
<fA21><s1>2011</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>27047</s2>
<s5>354000507873660110</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2011 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>24 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>11-0504707</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Antiviral therapy : (London)</s0>
</fA64>
<fA66 i1="01"><s0>GBR</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Background: Antiviral activity of TMC435, an oral, once-daily, HCV NS3/4A protease inhibitor, was evaluated with pegylated interferon-α2a/ribavirin (P/R) in HCV genotype-1 patients. Methods: Optimal Protease inhibitor Enhancement of Response to TherApy (OPERA-1; TMC435-C201; NCT00561353) is a Phase IIa, randomized, placebo-controlled study. Treatment-naive patients (n=7<sub>4</sub>
) received 25, 75 or 200 mg TMC435 once daily, or placebo for 7 days followed by 21 days of triple therapy with P/R, or triple therapy for 28 days. Treatment-experienced patients (n=3<sub>7</sub>
; 56.8% with cirrhosis) received 75, 150 or 200 mg TMC435 once daily, or placebo with P/R for 28 days. Patients continued P/R up to week 48. Results: Treatment-naive patients who received initial monotherapy had a rapid decline in HCV RNA by day 3. At day 7, HCV RNA reductions were greatest for the 75 and 200 mg doses (0.02, -2.63, -3.43 and -4.13 log<sub>10</sub>
 IU/ml for placebo, and TMC435 25, 75 and 200 mg, respectively). At day 28, all patients who received triple therapy with TMC435 75 or 200 mg had HCV RNA<25 IU/ml versus 4/9 for placebo. In total, 18/28 treatment-experienced patients (9/9 prior relapsers, 9/19 non-responders) who received TMC435 had HCV RNA<25 IU/ml at day 28 versus 0/9 for placebo; similar results were observed for the 150 and 200 mg doses. Most adverse events were grade 1/2. No relevant changes in laboratory parameters occurred, except mild and reversible bilirubin elevations, mostly at the 200 mg dose. Conclusions: Once-daily TMC435 with P/R showed potent, dose-dependent antiviral activity over 28 days, and had a favourable tolerability profile.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B02S05</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B05C02G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Dose journalière unique</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Single daily dose</s0>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Dosis diaria única</s0>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Association médicamenteuse</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Drug combination</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Asociación medicamentosa</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Forme pégylée</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Pegylated form</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Forma pegilada</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Cytokine</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Cytokine</s0>
<s5>04</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Citoquina</s0>
<s5>04</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Interféron</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Interferon</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Interferón</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>05</s5>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Ribavirine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Ribavirin</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Ribavirina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>06</s5>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Hépatite virale C</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>Viral hepatitis C</s0>
<s5>07</s5>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Hepatítis virica C</s0>
<s5>07</s5>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Génotype</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Genotype</s0>
<s5>08</s5>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Genotipo</s0>
<s5>08</s5>
</fC03>
<fC03 i1="09" i2="X" l="FRE"><s0>Typage</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="ENG"><s0>Typing</s0>
<s5>09</s5>
</fC03>
<fC03 i1="09" i2="X" l="SPA"><s0>Tipificación</s0>
<s5>09</s5>
</fC03>
<fC03 i1="10" i2="X" l="FRE"><s0>Homme</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="ENG"><s0>Human</s0>
<s5>10</s5>
</fC03>
<fC03 i1="10" i2="X" l="SPA"><s0>Hombre</s0>
<s5>10</s5>
</fC03>
<fC03 i1="11" i2="X" l="FRE"><s0>Malade</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="ENG"><s0>Patient</s0>
<s5>11</s5>
</fC03>
<fC03 i1="11" i2="X" l="SPA"><s0>Enfermo</s0>
<s5>11</s5>
</fC03>
<fC03 i1="12" i2="X" l="FRE"><s0>Randomisation</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="ENG"><s0>Randomization</s0>
<s5>12</s5>
</fC03>
<fC03 i1="12" i2="X" l="SPA"><s0>Aleatorización</s0>
<s5>12</s5>
</fC03>
<fC03 i1="13" i2="X" l="FRE"><s0>Antiviral</s0>
<s5>23</s5>
</fC03>
<fC03 i1="13" i2="X" l="ENG"><s0>Antiviral</s0>
<s5>23</s5>
</fC03>
<fC03 i1="13" i2="X" l="SPA"><s0>Antiviral</s0>
<s5>23</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Virose</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Viral disease</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Virosis</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Infection</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Infección</s0>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Analogue de nucléoside</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Nucleoside analog</s0>
<s5>37</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Análogo nucleósido</s0>
<s5>37</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie de l'appareil digestif</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Digestive diseases</s0>
<s5>38</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Aparato digestivo patología</s0>
<s5>38</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Pathologie du foie</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Hepatic disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Hígado patología</s0>
<s5>39</s5>
</fC07>
<fN21><s1>346</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
<affiliations><list><country><li>Allemagne</li>
<li>Belgique</li>
<li>France</li>
<li>Irlande (pays)</li>
<li>Pays-Bas</li>
<li>Pologne</li>
<li>Royaume-Uni</li>
<li>États-Unis</li>
</country>
<region><li>Angleterre</li>
<li>Basse-Saxe</li>
<li>District de Leipzig</li>
<li>Grand Londres</li>
<li>Hollande-Septentrionale</li>
<li>New Jersey</li>
<li>Région de Bruxelles-Capitale</li>
<li>Saxe (Land)</li>
</region>
<settlement><li>Amsterdam</li>
<li>Bruxelles</li>
<li>Hanovre</li>
<li>Leipzig</li>
<li>Londres</li>
</settlement>
<orgName><li>Université libre de Bruxelles</li>
</orgName>
</list>
<tree><country name="Allemagne"><region name="Basse-Saxe"><name sortKey="Manns, Michael" sort="Manns, Michael" uniqKey="Manns M" first="Michael" last="Manns">Michael Manns</name>
</region>
<name sortKey="Berg, Thomas" sort="Berg, Thomas" uniqKey="Berg T" first="Thomas" last="Berg">Thomas Berg</name>
</country>
<country name="Pays-Bas"><region name="Hollande-Septentrionale"><name sortKey="Reesink, Henk" sort="Reesink, Henk" uniqKey="Reesink H" first="Henk" last="Reesink">Henk Reesink</name>
</region>
</country>
<country name="Royaume-Uni"><region name="Angleterre"><name sortKey="Dusheiko, Geoffrey" sort="Dusheiko, Geoffrey" uniqKey="Dusheiko G" first="Geoffrey" last="Dusheiko">Geoffrey Dusheiko</name>
</region>
</country>
<country name="Pologne"><noRegion><name sortKey="Flisiak, Robert" sort="Flisiak, Robert" uniqKey="Flisiak R" first="Robert" last="Flisiak">Robert Flisiak</name>
</noRegion>
</country>
<country name="France"><noRegion><name sortKey="Marcellin, Patrick" sort="Marcellin, Patrick" uniqKey="Marcellin P" first="Patrick" last="Marcellin">Patrick Marcellin</name>
</noRegion>
</country>
<country name="Belgique"><region name="Région de Bruxelles-Capitale"><name sortKey="Moreno, Christophe" sort="Moreno, Christophe" uniqKey="Moreno C" first="Christophe" last="Moreno">Christophe Moreno</name>
</region>
<name sortKey="Lenz, Oliver" sort="Lenz, Oliver" uniqKey="Lenz O" first="Oliver" last="Lenz">Oliver Lenz</name>
<name sortKey="Meyvisch, Paul" sort="Meyvisch, Paul" uniqKey="Meyvisch P" first="Paul" last="Meyvisch">Paul Meyvisch</name>
<name sortKey="Peeters, Monika" sort="Peeters, Monika" uniqKey="Peeters M" first="Monika" last="Peeters">Monika Peeters</name>
<name sortKey="Verloes, Rene" sort="Verloes, Rene" uniqKey="Verloes R" first="Rene" last="Verloes">Rene Verloes</name>
</country>
<country name="États-Unis"><region name="New Jersey"><name sortKey="Sekar, Vanitha" sort="Sekar, Vanitha" uniqKey="Sekar V" first="Vanitha" last="Sekar">Vanitha Sekar</name>
</region>
</country>
<country name="Irlande (pays)"><noRegion><name sortKey="Simmen, Kenneth" sort="Simmen, Kenneth" uniqKey="Simmen K" first="Kenneth" last="Simmen">Kenneth Simmen</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Musique/explor/OperaV1/Data/PascalFrancis/Checkpoint

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000121 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Checkpoint/biblio.hfd -nk 000121 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Musique
   |area=    OperaV1
   |flux=    PascalFrancis
   |étape=   Checkpoint
   |type=    RBID
   |clé=     Pascal:11-0504707
   |texte=   Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial
}}

This area was generated with Dilib version V0.6.21.
Data generation: Thu Apr 14 14:59:05 2016. Site generation: Thu Oct 8 06:48:41 2020

	Serveur d'exploration sur l'opéra
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Serveur d'exploration sur l'opéra

Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial

Rapid viral response of once-daily TMC435 plus pegylated interferon/ribavirin in hepatitis C genotype-1 patients: a randomized trial

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri